Developed at the Radiopharmaceutical Application and Research Centre (RÜAG) within our university, ANKÜKOLİN represents our country’s scientific and technological production capacity in the field of nuclear medicine.

As one of the most concrete and successful examples of the Public-University-Industry Collaboration (KÜSİ) model, our product has been included in the Social Security Institution’s (SGK) SUT reimbursement list as the first domestically produced radiopharmaceutical to be licensed by the Turkish Ministry of Health.

From Scientific Production to Social Benefit

This development ensures that academic research does not remain merely theoretical but, through public-private partnership, is transformed into a registered product that directly serves society. The inclusion of the F-18 Florocolin PET imaging method, used in the diagnosis of parathyroid adenoma, within the reimbursement scope facilitates patients’ access to advanced diagnostic methods using domestic resources, thereby making a critical contribution to diagnostic and treatment processes.

Produced with a 12-hour shelf life and high-precision calibration standards (GMP), ANKÜKOLİN is a strategic output that reduces Turkey’s reliance on external sources within the healthcare ecosystem. We congratulate all our academics, researchers and strategic business partners who have contributed to this success story, which transforms science into a force that generates value for society.

May it bring benefit to our country and our academic community.